FSD Pharma Inc. (CVE:HUG – Free Report) – Equities researchers at Singular Research issued their Q1 2024 earnings per share (EPS) estimates for FSD Pharma in a report released on Tuesday, May 7th. Singular Research analyst B. Cook forecasts that the company will post earnings of ($0.07) per share for the quarter. Singular Research currently has a “Buy-Venture” rating on the stock. Singular Research also issued estimates for FSD Pharma’s Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.16) EPS.
FSD Pharma (CVE:HUG – Get Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported C($0.05) earnings per share for the quarter.
FSD Pharma Stock Performance
Read More
- Five stocks we like better than FSD Pharma
- How to Invest in the FAANG Stocks
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- How to Use the MarketBeat Excel Dividend Calculator
- Generac Powers Ahead on the Electrification Mega-Trend
- The How and Why of Investing in Gold Stocks
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
